Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
MWN-AI** Summary
Clearmind Medicine Inc. (Nasdaq: CMND), a Vancouver-based biotech company specializing in neuroplastogen-derived therapeutics, has advanced participant enrollment for the third cohort of its Phase I/IIa clinical trial of CMND-100, a promising non-hallucinogenic treatment for Alcohol Use Disorder (AUD). Following positive topline results from the second cohort that highlighted the treatment's safety and tolerability, the company has received unanimous approval from its Data and Safety Monitoring Board (DSMB) to proceed with this next phase. Leading research institutions such as Yale University, Johns Hopkins University, and Tel Aviv Sourasky Medical Center will host participant recruitment, signaling strong momentum for CMND-100.
Dr. Adi Zuloff-Shani, CEO of Clearmind, expressed enthusiasm about the clinical trial's progression, emphasizing the potential of CMND-100 to address critical unmet needs in AUD treatment without requiring adjunct psychotherapy, thus ensuring accessibility and discretion for patients. Clearmind Medicine’s commitment to developing innovative, effective, and affordable therapeutic solutions is evident in their ongoing research endeavors.
The multinational, multicenter study not only evaluates the safety and pharmacokinetics of CMND-100 but also its preliminary efficacy in patients with moderate to severe AUD. With a robust intellectual property portfolio encompassing nineteen patent families and 31 granted patents, Clearmind aims to commercialize its novel compounds as regulated medicines or supplements.
As Clearmind continues to navigate the complexities of clinical trials and regulatory hurdles, investors and market observers will closely monitor the outcomes of this promising study. For more information, visit Clearmind’s official website or reach out to their investor relations contacts.
MWN-AI** Analysis
Clearmind Medicine Inc. (Nasdaq: CMND) is entering a significant phase in its clinical journey with the recruitment for the third cohort of the Phase I/IIa trial for CMND-100, a treatment aimed at Alcohol Use Disorder (AUD). Recent positive topline results from the second cohort have bolstered investor confidence and may present a promising opportunity for stakeholders in the biotech sector.
With leading institutions like Yale and Johns Hopkins involved in the trial, the credibility and visibility of Clearmind Medicine are notably enhanced. The unanimous approval from the Data and Safety Monitoring Board emphasizes the safety and tolerability of CMND-100, which may encourage both institutional and retail investors to consider positioning themselves in Clearmind’s stock.
As the company pursues FDA approval for this innovative therapy, it is essential to evaluate the broader market context. The demand for effective treatments for AUD is significant, given the ongoing global health crisis surrounding substance use disorders. Clearmind's focus on non-hallucinogenic alternatives could potentially tap into a niche market that prioritizes safety and accessibility, particularly as mental health and addiction treatment continue to receive increased attention.
Investors should monitor upcoming trial results closely, as these will be critical to determining the long-term viability of CMND-100. If the subsequent cohorts maintain the trend of positive outcomes, anticipation around FDA approval may lead to share price appreciation. However, potential investors should also remain cognizant of the risks inherent in clinical-stage biotech investments, including regulatory uncertainty and market volatility.
In conclusion, Clearmind Medicine appears well-positioned for growth in the evolving landscape of mental health therapeutics. The company's commitment to innovative, non-hallucinogenic treatments could lead to substantial returns for investors who take a well-timed strategic position in the stock.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Vancouver, Canada, March 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the continuation of participant enrollment for the third cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).
The recruitment follows the positive topline results recently reported from the second cohort, which demonstrated continued safety and tolerability, building on the favorable outcomes from prior cohorts. The Company’s Data and Safety Monitoring Board (DSMB) has reviewed the data and provided unanimous approval to proceed, enabling enrollment in this next phase.
The Phase I/IIa clinical trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. Participant recruitment for the third cohort at leading sites, including Yale University, Johns Hopkins University, and Tel Aviv Sourasky Medical Center, reflecting strong momentum and confidence in CMND-100 as a potential breakthrough therapy for AUD.
“Building on the encouraging results from our first and second cohort, we are excited on progressing with the clinical trial at these prestigious institutions,” said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. “The positive data we continue to receive from our clinical trial, reinforce CMND-100’s potential as a safe and well tolerated, non-hallucinogenic treatment option that addresses the critical unmet needs in alcohol use disorder, without requiring adjunct psychotherapy, making this treatment accessible and discrete. We remain committed to progressing this trial to bring innovative, safe and affordable solutions to patients in need.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and progress of its clinical trials, advancing to patient enrollment for the fourth cohort, CMND-100’s potential as a safe, non-hallucinogenic treatment option that addresses the critical unmet needs in alcohol use disorder, without requiring adjunct psychotherapy and its commitment to progressing its clinical trial to bring innovative, safe and affordable solutions to patients in need. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ**
What specific outcomes from the second cohort of Clearmind Medicine Inc. CMND's clinical trial for Alcohol Use Disorder have contributed to the confidence in moving forward with the third cohort of the study?
How does Clearmind Medicine Inc. CMND plan to address potential regulatory hurdles as it progresses through the phases of clinical trials for its MEAI-based drug candidate?
Given the positive safety and efficacy results reported by Clearmind Medicine Inc. CMND, what steps will be taken to attract additional investment for future trials and product development?
In what ways does Clearmind Medicine Inc. CMND's approach to treating Alcohol Use Disorder differ from traditional therapies that often require adjunct psychotherapy?
**MWN-AI FAQ is based on asking OpenAI questions about Clearmind Medicine Inc. (NASDAQ: CMND).
NASDAQ: CMND
CMND Trading
-13.95% G/L:
$0.8046 Last:
186,240 Volume:
$0.83 Open:
